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ORIGINAL INVESTIGATION
Association of TyG index and TG/HDL-C 
ratio with arterial stiffness progression 
in a non-normotensive population
Zhiyuan Wu1,3†, Di Zhou1†, Yue Liu1, Zhiwei Li1, Jinqi Wang1, Ze Han1, Xinlei Miao1, Xiangtong Liu1, Xia Li2, 
Wei Wang3, Xiuhua Guo1,2* and Lixin Tao1,2*  
Abstract 
Background: Cross-sectional studies have reported that insulin resistance (IR) is associated with arterial stiffness. 
However, the relationship between IR and arterial stiffness progression remains unclear. This study aims to evaluate 
the association of triglyceride glucose (TyG) index and triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) 
ratio with arterial stiffness progression in a non-normotensive population.
Methods: A total of 1895 prehypertensive (systolic pressure 120–139 mmHg or diastolic pressure 80–90 mmHg) or 
hypertensive (systolic pressure ≥ 140 mmHg or diastolic pressure ≥ 90 mmHg or using antihypertensive medication) 
participants were enrolled in 2013 and 2014, and followed until December 31, 2019. Arterial stiffness progression 
was measured by brachial-ankle pulse wave velocity (baPWV) change (absolute difference between baseline and 
last follow-up), baPWV change rate (change divided by following years), and baPWV slope (regression slope between 
examination year and baPWV).
Results: During a median follow-up of 4.71 years, we observed an increasing trend of baPWV in the population. 
There were linear and positive associations of the TyG index and TG/HDL-C ratio with the three baPWV parameters. 
The difference (95% CI) in baPWV change (cm/s) comparing participants in the highest quartile versus the lowest of 
TyG index and TG/HDL-C ratio were 129.5 (58.7–200.0) and 133.4 (52.0–214.9), respectively. Similarly, the evaluated 
baPWV change rates (cm/s/year) were 37.6 (15.3–60.0) and 43.5 (17.8–69.2), while the slopes of baPWV were 30.6 
(9.3–51.8) and 33.5 (9.0–58.0). The observed association was stronger in the hypertensive population.
Conclusion: Our study indicates that the TyG index and TG/HDL-C ratio are significantly associated with arterial stiff-
ness progression in hypertensive population, not in prehypertensive population.
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Background
Hypertension has caused a heavy economic burden 
worldwide, becoming a challenging public health issue. 
In 2010, 31.1% of adults around the world were reported 
to have hypertension [1]. Among Chinese adults aged 
35–75 years, nearly half are diagnosed with hypertension, 
the incidence is still steadily increasing, and the onset age 
is becoming younger [2]. Among hypertensive patients, 
arterial stiffness is a common vascular complication and 
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is also an independent risk factor and predictor of other 
cardiovascular and cerebrovascular diseases [3, 4], such 
as coronary heart disease (CHD) and stroke. Therefore, it 
is of great importance to focus on the progression of arte-
rial stiffness in the hypertensive population and identify 
the early related factors of arterial stiffness [5–7].
Disorders of glucose and lipid metabolism are a com-
mon pathophysiological feature accompanying patients 
with hypertension, while insulin resistance (IR) exten-
sively participates in this biological process [8]. The 
hyperinsulinaemic-euglycaemic clamp is the gold stand-
ard for evaluating the status of IR [9]. However, this 
assessment process is expensive and complex and is not 
ideal for routine clinical monitoring. Recently, some 
novel and simple indicators have been reported to be 
reliable surrogate indexes of IR, such as the triglyceride-
glucose (TyG) index and the triglyceride to high-density 
lipoprotein cholesterol (TG/HDL-C) ratio. Compared 
with the hyperinsulinaemic-euglycaemic clamp, the TyG 
index has a high sensitivity of 96.5% and a specificity of 
85.0% for the diagnosis of IR [10], which has also been 
reported to be associated with diabetes in Chinese popu-
lation [11]. Many studies have found that these surrogate 
indexes are independent risk factors for some cerebro-
cardiovascular diseases [12–14]. Moreover, IR-related 
indexes are associated with arterial stiffness [15–19]. 
However, these studies are all based on general popula-
tions. Recently, Li et  al. [20] found that the TyG index 
is positively associated with brachial-ankle pulse wave 
velocity (baPWV) in hypertensive patients. However, this 
study is a cross-sectional study without follow-up. More-
over, the association between the TG/HDL-C ratio and 
arterial stiffness remains unreported.
Therefore, we aimed to comprehensively investigate the 
association between the TyG index and TG/HDL-C ratio 
with arterial stiffness progression in prehypertensive and 




The Beijing health management cohort (BHMC) is an 
open cohort study established in 2008 in Beijing, China, 
with new individuals recruited annually. The BHMC 
study was conducted based on health examination pop-
ulations from the Beijing Xiaotangshan Examination 
Center and Beijing Physical Examination Center. BHMC 
was designed to investigate the risk factors and biomark-
ers for metabolism-related diseases, and the recruited 
individuals were asked to take an annual health exami-
nation, including physical examination (anthropometry 
variables, blood pressures), face-to-face questionnaire 
survey (demographic variables, lifestyles, diseases 
history, medication history) and biochemical examina-
tion. Details of the study design have been described 
previously [21]. The arterial stiffness-related variables, 
such as baPWV and ankle brachial index (ABI), were 
available from 2013. Therefore, individuals taking health 
examinations in 2013 and 2014 were recruited in this 
current study as a baseline. Of 22,746 participants who 
underwent health examination at baseline, 2327 were 
confirmed to have prehypertension or hypertension. To 
minimize the possible influence of medication on glu-
cose and lipid levels, 42 participants using antidiabetic 
agents and 52 participants using lipid-lowering agents 
were excluded. In addition, we excluded 101 participants 
with CHD, stroke or other cerebrocardiovascular dis-
eases. Nineteen participants with any malignancy were 
excluded. Twenty-three participants from whom we were 
unable to collect the required data at baseline and 188 
participants lost to follow-up, defined as without health 
examination records until 2019, were further excluded 
from the analyses. Finally, this study was restricted to a 
subset of 1895 participants with complete data, which 
were used in the final analyses, as shown in Fig. 1. Most 
of the participants (98%) enrolled in this current study 
came from a work unit in Beijing, and there were a total 
of 407 units included.
This study was in accordance with the principles of 
the Declaration of Helsinki and approved by the Ethics 
Committee of Capital Medical University (grant number: 
2020SY031). All participants provided written informed 
consent before taking part in this study.
Data collection and definitions
The demographic characteristics, lifestyle, and medi-
cation-related information were collected via a stand-
ard questionnaire by our trained staff, including age, 
sex, occupation, smoking status, drinking status, regu-
lar physical activity, diagnosis history of diseases and 
medication information. Occupation in this current 
study was classified into ‘manager’, ‘technician or profes-
sional’, ‘worker’ and ‘retired’. Smoking status was defined 
as ‘current smoker’, ‘former smoker’ and ‘never smoked’. 
Drinking status was defined as ‘current drinking’ and ‘no 
current drinking’. Physical activity was defined as hav-
ing moderate or intense exercise ‘ ≥ 80  min per weak’ 
and ‘ < 80  min per week or none’. The physical and bio-
chemical examination data were acquired from the elec-
tronic medical record system. Body mass index (BMI) 
was calculated as weight (in kilograms)/height^2 (in 
metres squared). Systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) were presented as the 
average of two measurements on the right arm using 
a sphygmomanometer after resting for at least 10  min. 
Based on the JNC-7 criteria [22], hypertension status 
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was defined as SBP ≥ 140  mmHg or DBP ≥ 90  mmHg 
or use of any antihypertensive medication. Prehyper-
tension status was defined as SBP of 120–139  mmHg 
or DBP of 80–89  mmHg. The mean arterial pressure 
(MAP) was calculated as 1/3*SBP + 2/3*DBP. A higher 
vascular stiffness increases pulse pressure (PP), while PP 
could increase SBP and decrease DBP to a small extent. 
Therefore, the MAP level was adjusted in the following 
analyses.
Blood samples were stored and measured in the central 
laboratory of Beijing Xiaotangshan Examination Center 
or Beijing Physical Examination Center using the Olym-
pus Automatic Biochemical Analyser (Hitachi 747; Tokyo, 
Japan). Serum total cholesterol (TC), triglyceride (TG), high-
density lipoprotein cholesterol (HDL-C), and low-density 
lipoprotein cholesterol (LDL-C) were measured with the 
enzymatic colour metric method. The estimated glomerular 
filtration rate (eGFR) was calculated using the Chronic Kid-
ney Disease Epidemiology Collaboration (CKD-EPI 2009) 
serum creatinine equation [23]. Fasting blood glucose (FBG) 
was defined as the glucose concentrations before breakfast 
after overnight fasting (no food, except drinking water, for 
at least 8–10  h), while two-hour postprandial blood glu-
cose (PBG) was measured 2  h after the beginning of fixed 
meals through finger blood tests. Diabetes was defined as 
FBG ≥ 7.0  mmol/L, PBG ≥ 11.1  mmol/L, glycated haemo-
globin (HbA1c) ≥ 6.5% or the use of any glucose-lowering 
medication according to the American Diabetes Association 
[24]. According to the Guidelines on Prevention and Treat-
ment of Dyslipidaemia for Chinese Adults [25], dyslipidae-
mia was defined as TG ≥ 2.3  mmol/L, TC ≥ 6.2  mmol/L, 
LDL-C ≥ 4.1  mmol/L, HDL-C < 1.0  mmol/L, or any lipid-
lowering medication. The TyG index was denoted as ln[TG 
(mm/L)*fasting glucose (mm/L)/2]. The TG/HDL-C ratio 
was calculated as TG (mm/L) divided by HDL-C (mm/L).
Assessment of baPWV
baPWV is a simple, noninvasive, automatic and widely 
used method in clinical practice and large population-
based studies. The baPWV was measured with an Omron 
Colin BP-203RPE III device (Omron Health Care, Kyoto, 
Japan). After more than 5 min of rest in the supine posi-
tion, 4 cuffs were wrapped around the bilateral brachia 
and ankles and then connected to a plethysmographic 
sensor and oscillometric pressure sensor. Semiconduc-
tor pressure sensors were used to assess the transmis-
sion time between the initial rises in both the brachial 
and tibial artery waves to record the pressure waveform. 
22,746 participants (aged≥20) underwent 
health examination in 2013 and 2014 
2,327 participants eligible for inclusion as baseline
20,419 participants were excluded with normal 
blood pressure 
2,083 followed from 2013-2014 until 
December 31, 2019
1,895 enrolled in final analysis
Excluded:
19 participants with any malignancy
101 participants with CHD, stroke or other 
cerebro-cardiovascular diseases
42 participants with antidiabetic and 59 with lipid-
lowering medicine
23 participants unable to collect the required data 
188 participants were lost to follow up
Fig. 1 Flow chart of the study population
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The distance between sampling points of baPWV was 
determined based on the height of the subjects. The time 
interval between the wave front of the brachial waveform 
and the ankle waveform was expressed as the time inter-
val between the brachium and ankle (∆Tba). The final 
baPWV was calculated as
La was the path length from the suprasternal notch to 
the ankle, and Lb was the path length from the supraster-
nal notch to the brachium using the following equations:
The detailed process has been described in a previous 
study [26]. The maximum value of baPWV on the left and 
right sides was chosen as the final result of baPWV. The 
baPWV was measured at baseline and at the follow-up 
visit. The baPWV change was calculated as the baPWV 
value at baseline minus the baPWV value at the last visit 
during follow-up. The baPWV change rate was calcu-
lated as the value of baPWV change divided by the time 
distance between baseline and last visit. The slope of 
baPWV was defined as the linear regression slope with 
examination year as the independent variable and multi-
ple baPWV measurements as the dependent variable.
Statistical analysis
Baseline characteristics are presented as the mean 
(standard deviation, SD), median [interquartile range, 
IQR] or number (percentage), as appropriate. Differ-
ences in baPWV change, baPWV change rate and slope 
of baPWV among groups were compared using the 
Kruskal–Wallis test.
Multivariate linear regression models were used to esti-
mate the association of the TyG index and TG/HDL-C 
ratio with the absolute change, change rate and slope 
of baPWV. The TyG index and TG/HDL-C ratio were 
both analysed as continuous variables and categorized 
into quartiles. To adjust for potential confounding fac-
tors, three models were established as follows: model 1 
adjusted for age and sex; model 2 adjusted for age, sex, 
BMI, smoking status, drinking status, physical activity, 
diabetes, dyslipidaemia, baPWV at baseline, and MAP at 
baseline and last follow-up; model 3 further adjusted for 
FBG (HDL-C if TG/HDL-C ratio analysed), triglyceride, 
PBG, LDL-C, eGFR, uric acid, homocysteine, and use of 
antidiabetic, lipid-lowering, or antihypertensive medica-
tions at baseline and follow-up. The regression coefficient 
and its 95% confidence interval (CI) are presented. Spear-
man’s correlation analyses of the TyG index and TG/
(1)baPWV = (La− Lb)/�Tba
(2)
La = 0.8129× height of the participant (in cm)+ 12.328
(3)
Lb = 0.2195× height of the participant (in cm)− 2.0734
HDL-C ratio with other common cardiometabolic risk 
factors were performed. To identify the interaction of 
insulin resistance indexes and other variables, the inter-
active terms were tested in the model.
All of the analyses presented above were conducted 
using R software (version 3.6.3). The difference was con-
sidered statistically significant at two-sided P < 0.05.
Results
The final analysis included 1,895 individuals. During the 
follow-up period, a total of 986 recruited individuals 
attended health examinations twice, 612 had three exam-
inations and 297 had four or five examinations. The mean 
age of the population was 61.90 ± 12.75 years, and 1,477 
(77.9%) were men. At baseline, 1,013 (53.5%) partici-
pants were diagnosed with hypertension, and 882 (46.5%) 
were diagnosed with prehypertension, among which 335 
participants progressed to hypertension at the last visit 
of follow-up. The median values of the baPWV change, 
the baPWV change rate and the slope of baPWV were 
46 cm/s, 9  cm/s/year and 8.11 in the whole population, 
respectively, as shown in Table 1. The detailed character-
istics according to the quartiles of the TyG index and TG/
HDL-C ratio are presented in Additional file 1: Table S1 
and Table S2.
We observed linear and positive associations of the 
TyG index and TG/HDL-C ratio with  the baPWV 
change, baPWV change rate and slope of baPWV, as 
shown in Fig. 2. In the fully adjusted model (model 3), a 
one-unit increase in the TyG index was associated with 
a 149.6  cm/s increase in baPWV change, a 40.4  cm/s/
year increase in the baPWV change rate, and a 34.9 cm/s 
increase in the baPWV slope. The average increases of 
baPWV change, change rate and slope, comparing partic-
ipants in the highest quartile versus the lowest of the TyG 
index, were 129.5 cm/s (P for trend: < 0.001), 37.6 cm/s/
year (P for trend: < 0.001), and 30.6 (P for trend: 0.002), 
respectively. Similarly, a one-unit increase in the TG/
HDL-C ratio was associated with a 37.1 cm/s increase in 
baPWV change, a 9.8 cm/s/year increase in the baPWV 
change rate, and an 8.0  cm/s increase in the baPWV 
slope. The average increases in baPWV change, change 
rate and slope, comparing participants in the highest 
quartile versus the lowest quartile of the TG/HDL-C 
ratio, were 133.4  cm/s (P for trend: 0.002), 43.5  cm/s/
year (P for trend: 0.001), and 33.5 (P for trend: 0.004), 
respectively. The detailed regression results are shown 
in Tables  2 and 3. The distributions of baPWV change, 
baPWV change rate and slope of baPWV among the 
quartile groups according to the TyG index are shown 
in Fig.  3A–C. The distributions of baPWV parameters 
among the quartile groups according to the TG/HDL-C 
ratio are shown in Fig. 3D–F. To identify the significant 
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interaction of the TyG index and TG/HDL-C ratio with 
other covariates, such as age, sex, BMI, diabetes, dyslipi-
daemia, kidney function and life habits, we tested all of 
the interaction terms in the fully adjusted model (if not 
stratified). We found that only the associations of the 
TyG index and TG/HDL-C ratio with baPWV parameters 
were significantly different between prehypertensive and 
hypertensive populations. The strength of the associa-
tions of the TyG index and TG/HDL-C ratio with arterial 
stiffness progression were dominant in the hypertensive 
population, as shown in Additional file  1: Table  S3 and 
Fig. 4. In addition, we fitted the joint TyG index and TG/
HDL-C ratio in the fully adjusted model to evaluate the 
joint association with artery stiffness progression. There 
was a stronger association between the TyG index and 
the absolute change, change rate and slope of baPWV 
than the TG/HDL-C ratio, as shown in Additional file 1: 
Table S4.
The correlation coefficients of the TyG index and TG/
HDL-C ratio with other common cardiometabolic risk 
factors are described in Additional file 1: Figure S1. There 
were weak correlations of the TyG index and TG/HDL-C 
ratio with BMI, SBP, DBP, FBG, PBG, HbA1c, TC, LDL-
C, serum uric acid, eGFR and homocysteine (Spearman’s 
coefficients less than 0.5), apart from TG and HDL-C.
Discussion
In this prospective cohort study, we found that a higher 
TyG index and TG/HDL-C ratio were associated with 
a higher risk of arterial stiffness progression in the 
hypertensive population, during a median follow-up of 
4.71  years. The observed associations were still signifi-
cant after adjusting for important confounding factors, 
including age, BMI, blood pressure, medication use, life-
style habits, serum uric acid, serum homocysteine, eGFR, 
diagnosis of diabetes and dyslipidaemia, which are tra-
ditional cardiometabolic risk factors and are related to 
arterial stiffness progression. TyG index and TG/HDL-C 
ratio deserve more attention in clinical practice for pre-
venting artery stiffness and other cerebrocardiovascular 
complications in the hypertensive population.
Artery stiffness is a severe adverse event in the hyper-
tensive population. On the other hand, arterial stiffness 
can lead to other macro- and microvascular complica-
tions and a series of organic damages, such as cerebro-
vascular diseases and renal damage [3, 27–29]. Moreover, 
research has found that some biological factors precede 
arterial stiffness progression in patients with hyperten-
sion, such as the duration of diabetes mellitus [30] and 
sodium sensitivity or resistance [31]. Therefore, identi-
fying early and reliable related factors associated with 
artery stiffness in the hypertensive population is of great 
importance. The TyG index and TG/HDL-C ratio have 
Table 1 Characteristics of the study population
Data are the mean (SD), median [IQR] or number (%)
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood 
pressure; MAP: mean arterial pressure; FBG: fasting blood glucose; PBG: 
postprandial blood glucose; HbA1c: glycated haemoglobin; HDL-C: high-density 
lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; eGFR: 
estimated glomerular filtration rate; TyG: triglyceride glucose; baPWV: brachial-
ankle pulse wave velocity
Characteristics (N = 1895)
At baseline
 Age (years) 61.90 (12.75)
 Sex (men, %) 1477 (77.9)
 Occupation (n, %)
  Manager 392 (20.7)
  Technician or professional 214 (11.3)
  Worker 187 (9.9)
  Retired 1102 (58.1)
 BMI 26.52 (3.22)
 Physical activity (n, %) 964 (50.9)
 Smoking status: none/former/current 
(n, %)
1128 (59.6)/285 (15.0)/482 (25.4)
 Current drinking (n, %) 844 (44.5)
 SBP (mmHg) 139.64 (12.69)
 DBP (mmHg) 78.67 (10.06)
 MAP (mmHg) 98.99 (8.60)
 Hypertension (n, %) 1013 (53.5)
 Antihypertensive medication (n, %) 267 (26.4)
 Diabetes (n, %) 323 (17.0)
 Dyslipidaemia (n, %) 773 (40.8)
 FBG (mmol/L) 5.79 (1.48)
 PBG (mmol/L) 7.72 (2.61)
 HbA1c (%) 5.94 (0.82)
 Triglyceride (mmol/L) 1.86 (1.62)
 Total cholesterol (mmol/L) 4.81 (0.98)
 LDL-C (mmol/L) 3.11 (0.88)
 HDL-C (mmol/L) 1.25 (0.32)
 eGFR (mL/min per 1.73  m2) 90.88 (26.05)
 Uric acid (μmol/L) 365.83 (84.67)
 Homocysteine (μmol/L) 12.74 (7.66)
 TyG index 1.42 [1.03,1.83]
 TG/HDL-C ratio 1.22 [0.78,1.96]
 baPWV (cm/s) 1538.00 [1392.00,1769.50]
At last visit of follow up
 baPWV (cm/s) 1603.00 [1412.00,1815.50]
 Change of baPWV (cm/s) 46.00 [− 251.00,309.50]
 Change rate of baPWV (cm/s/year) 9.00 [− 57.22,64.29]
 Slope of baPWV 8.11 [− 54.72,66.96]
 Hypertension (n, %) 1348 (71.1)
 Antihypertensive medication (n, %) 562 (41.7)
 Antidiabetic medication (n, %) 151 (8.0)
 Lipid-lowering medication (n, %) 273 (14.4)
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been reported to be associated with artery stiffness in 
the general population in previous studies. However, 
evidence in prehypertensive and hypertensive popula-
tions is scarce, except for the study by Li et al. [20], which 
reported that the TyG index is associated with evaluated 
baPWV in a hypertensive population based on a cross-
sectional design. Our study supplemented the evidence 
that the TyG index and TG/HDL-C ratio are associated 
with artery stiffness progression for the first time. We 
found that a higher TyG index and TG/HDL-C ratio were 
associated with an increased baPWV change, baPWV 
change rate and slope of baPWV in the hypertensive 
population based on a prospective cohort design.
The TyG index and TG/HDL-C ratio, have been of 
increasing interest at present. The TyG index and TG/
HDL-C ratio have high sensitivity and specificity for 
the diagnosis of insulin resistance compared with the 
hyperinsulinaemic-euglycaemic clamp and homeostatic 
model assessment in many populations [32, 33]. These 
two indicators have a high possibility of being easily 
applied in clinical practice for the early detection of IR, 
arterial stiffness and other diseases. Previous studies have 
also demonstrated the association of the TyG index with 
cardiovascular, cerebrovascular and other metabolic dis-
eases. In 2014, Fedchuk et al. [34] measured five steato-
sis biomarkers, including the TyG index, fatty liver index 
(FLI), NAFLD liver fat score (NAFLD-LFS), hepatic stea-
tosis index (HSI) and visceral adiposity index (VAI), and 
found that all five steatosis biomarkers could contribute 
to the early diagnosis of steatosis and were correlated 
with IR. In the Northern Shanghai Study, Zhao et  al. 
[17] concluded that an elevated TyG index was signifi-
cantly related to arterial stiffness and nephric microvas-
cular damage, which supported the clinical application 
of the TyG index for the assessment of vascular dam-
age. In recent years, several studies have also reported 
that the TyG index may predict several cardiovascular 
diseases, including acute coronary syndromes, sympto-
matic CHD and ischaemic stroke [35–39]. For the TG/
HDL-C ratio, in an 8-year Japan Diabetes Complications 
Study, Hirohito Sone et  al. [40] evaluated conventional 
lipid variables, such as TG, non-HDLC, TC/HDL-C 
ratio, LDL-C/HDL-C ratio, and TG/HDL-C ratio, for a 



































































































Fig. 2 The regression line of the TyG index and TG/HDL-C ratio with artery stiffness progression. A TyG index and baPWV change; B TyG index and 
baPWV change rate; C TyG index and slope of baPWV; D TG/HDL-C ratio and baPWV change; E TG/HDL-C ratio and baPWV change rate; F TG/HDL-C 
ratio and slope of baPWV
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Table 2 Association of the TyG index with the absolute change, change rate and slope of baPWV
Model 1: Adjusted age and sex; Model 2: Age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at baseline, and MAP at 
baseline and follow-up; Model 3: Model 2 plus FBG, triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, and use of antidiabetic, lipid-lowering, or antihypertensive 
medications at baseline and follow-up
model 1 model 2 model 3
β 95% CI P value β 95% CI P value β 95% CI P value
Change of baPWV (cm/s)
 TyG (continuous) 32.034 4.642–59.425 0.022 57.119 22.835–91.402 0.001 149.582 90.823–208.342 < 0.001
 Quartile 2 (ref: quartile 1) 59.745 10.509–108.982 0.017 61.086 12.582–109.59 0.014 76.297 28.63–123.964 0.002
 Quartile 3 85.613 36.416–134.81 0.001 93.631 43.889–143.373 < 0.001 102.562 52.08–153.044 < 0.001
 Quartile 4 74.957 25.494–124.42 0.003 98.555 37.584–159.526 0.002 129.525 58.723–200.326 < 0.001
 P for trend 0.002 < 0.001 < 0.001
Change rate of baPWV (cm/s/year)
 TyG (continuous) 11.892 3.415–20.368 0.006 17.974 7.307–28.642 0.001 40.372 21.853–58.891 < 0.001
 Quartile 2 (ref: quartile 1) 11.870 -3.385–27.125 0.127 12.122 -2.986–27.229 0.116 16.529 1.507–31.551 0.031
 Quartile 3 20.615 5.373–35.858 0.008 22.642 7.149–38.135 0.004 24.390 8.481–40.299 0.003
 Quartile 4 24.616 9.291–39.941 0.002 30.750 11.76–49.741 0.002 37.607 15.294–59.919 0.001
 P for trend 0.001 0.001 < 0.001
Slope of baPWV
 TyG (continuous) 9.570 1.538–17.601 0.020 14.238 4.121–24.355 0.006 34.874 17.238–52.51 < 0.001
 Quartile 2 (ref: quartile 1) 10.986 -3.469–25.441 0.136 10.888 -3.439–25.215 0.137 14.872 0.57–29.175 0.042
 Quartile 3 18.739 4.296–33.182 0.011 20.092 5.399–34.785 0.007 22.163 7.016–37.31 0.004
 Quartile 4 20.126 5.604–34.647 0.007 23.648 5.639–41.658 0.010 30.576 9.332–51.82 0.005
 P for trend 0.004 0.003 0.002
Table 3 Association of TG/HDL-C ratio with the absolute change, change rate and slope of baPWV
Model 1: adjusted age and sex; Model 2: age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at baseline, and MAP 
at baseline and follow-up; Model 3: Model 2 plus HDL-C, triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, and use of antidiabetic, lipid-lowering, or 
antihypertensive medications at baseline and follow-up
Model 1 Model 2 Model 3
β 95% CI P value β 95% CI P value β 95% CI P value
Change of baPWV (cm/s)
 TG/HDL-C ratio (continuous) 6.795 − 1.193 to 14.784 0.096 4.934 − 3.684 to 13.552 0.062 37.057 7.85–66.264 0.013
 Quartile 2 (ref: quartile 1) 70.320 21.037–119.604 0.005 68.883 19.964–117.802 0.006 75.317 24.101–126.534 0.004
 Quartile 3 83.153 34.299–132.007 0.001 89.453 38.544–140.362 0.001 84.036 25.516–142.556 0.005
 Quartile 4 131.912 82.542–181.282 < 0.001 142.938 78.525–207.35 < 0.001 133.420 51.949–214.891 0.001
 P for trend < 0.001 < 0.001 0.002
Change rate of baPWV (cm/s/year)
 TG/HDL-C ratio (continuous) 2.587 0.115–5.06 0.040 1.880 − 0.801 to 4.562 0.169 9.768 0.547–18.989 0.038
 Quartile 2 (ref: quartile 1) 14.121 − 1.149 to 29.392 0.070 13.621 − 1.616 to 28.857 0.080 19.486 3.325–35.646 0.018
 Quartile 3 23.979 8.842–39.117 0.002 25.543 9.687–41.399 0.002 29.615 11.15–48.08 0.002
 Quartile 4 38.237 22.94–53.534 < 0.001 40.369 20.307–60.431 < 0.001 43.511 17.804–69.217 0.001
 P for trend < 0.001 < 0.001 0.001
Slope of baPWV
 TG/HDL-C ratio (continuous) 2.253 − 0.089 to 4.595 0.060 4.507 1.425–6.048 0.045 7.973 0.801–22.317 0.035
 Quartile 2 (ref: quartile 1) 12.212 − 2.264 to 26.687 0.098 11.300 − 3.154 to 25.754 0.126 15.465 0.078–30.852 0.049
 Quartile 3 21.636 7.287–35.986 0.003 21.977 6.935–37.019 0.004 24.296 6.715–41.877 0.007
 Quartile 4 33.088 18.587–47.589 < 0.001 32.178 13.146–51.21 0.001 33.496 9.02–57.972 0.007
 P for trend < 0.001 < 0.001 0.004
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of these variables could predict CHD events in men and 
women. Marcello et al. [41] carried out a cross-sectional 
study to investigate the association between IR and TG/
HDL-C with CHD and concluded that HOMA-IR and 
TG/HDL-C are positively associated with CHD and may 
be useful as high-specificity indicators of CHD for risk 
stratification. These studies indicate that the TyG index 
and TG/HDL-C ratio are promising markers for future 
screening of metabolic diseases.
In the current study, we found that the evaluated TyG 
index and TG/HDL-C ratio were independently asso-
ciated with the progression of artery stiffness in the 
hypertensive population, while a significant association 
was not observed in the prehypertensive population. In 
a previous study [42], blood pressure and the hyperten-
sive state itself were reported to worsen the progression 
of arterial stiffness. In a review analysis [43], age and 
high blood pressure were the two main determinants of 
arterial stiffness. The findings in our study imply that 
the interaction between hypertensive status and insulin 
resistance leads to arterial stiffness progression, which 
means that people with hypertension should pay close 
attention to insulin resistance indexes to prevent artery 
stiffness. Although not completely elucidated, there are 
potential mechanisms linking the TyG index and TG/
HDL-C ratio with arterial stiffness. Insulin resistance is 
related with endothelial dysfunction, coagulation dys-
function, oxidative stress and inflammation, and car-
diac concentric remodeling [44]. Hyperglycemia and 
hyperinsulinemia, usually accompanied by hyperlipi-
demia, are characterized by increased intracellular cal-
cium concentration, increased collagen and advanced 
glycation end products, fibrosis and cellular hypertro-
phy, which reduce arterial elasticity through arterial 
remodeling especially in the hypertensive population, 
and lead to arterial stiffness [45, 46].
In addition, the TyG index and TG/HDL-C ratio, 
derived from fasting glucose, triglycerides and HDL-
C, showed weak correlations with other components of 
metabolic syndrome, which implies that the TyG index 
and TG/HDL-C ratio might precede the incidence of 
the insulin resistance components [47]. Therefore, the 
TyG index and TG/HDL-C ratio may be early biomark-
ers of insulin resistance and other metabolic diseases, 
which warrants further validation in other studies.
***
****



























































































































Fig. 3 The distributions of the absolute change, change rate and slope of baPWV among the quartile groups according to the TyG index (A–C) and 
TG/HDL-C ratio (D–F)
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The strengths of the present study include the prospec-
tive cohort design to explore the association of the TyG 
index and TG/HDL-C ratio with the progression of artery 
stiffness in prehypertensive and hypertensive popula-
tions, the adjustment of the potential confounding fac-
tors, and handling the TyG index and TG/HDL-C ratio 
as both continuous variables and categorical variables 
to enhance the reliability of our findings. However, the 
results should be interpreted in the context of some limi-
tations. First, the sample size was relatively small, and the 
95% CI of the estimated effect was wide. In the prehyper-
tensive population, we only observed the evaluated ten-
dency of baPWV change, baPWV change rate and slope 
of baPWV without statistical significance. The observed 
results in this single-centre study need further valida-
tion to generalize the associations in other populations 
and to evaluate the underlying biological mechanism 
between insulin resistance and artery stiffness progres-
sion. Second, the use of antihypertensive medication was 
considered in this analysis. However, we failed to collect 
the specific types of antihypertensive agents, given that 
different antihypertensive medications could have differ-
ent influences on baPWV measurements. Data on anti-
platelet medication were unavailable. Third, we analysed 
the association of the TyG index and TG/HDL-C ratio at 
baseline with artery stiffness progression in the current 
study, and evaluation of the dynamic TyG index and TG/
HDL-C ratio was needed with multiple measurements 
and related methods, such as trajectory analysis.
Conclusion
In summary, our findings indicate that the TyG index 
and TG/HDL-C ratio are significantly associated with 
arterial stiffness progression in hypertensive population, 
not in prehypertensive population. Monitoring the TyG 
index and TG/HDL-C ratio deserves more attention in 
clinical practice for the early prevention of arterial stiff-

























































































































































P interaction = 0.025 P interaction = 0.028 P interaction = 0.036
F
P interaction = 0.024 P interaction = 0.031 P interaction = 0.033
Fig. 4 Associations of the TyG index and TG/HDL-C ratio with the absolute change, change rate and slope of baPWV in prehypertensive and 
hypertensive populations*. *Adjusted for age, sex, BMI, smoking status, drinking status, physical activity, diabetes, dyslipidaemia, baPWV at 
baseline, FBG (HDL-C if TG/HDL-C ratio analysed), triglyceride, PBG, LDL-C, eGFR, uric acid, homocysteine, MAP at baseline and follow up, and use of 
antidiabetic, lipid-lowering, or antihypertensive medications at baseline and follow up
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